Epidemiology of Hepatitis C in Pregnancy in North Central Florida: A Reassessment of Risks
ACOG ePoster. Spiryda L. Apr 27, 2018; 211513; 10I
Lisa Spiryda
Lisa Spiryda
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Rate & Comment (0)
Introduction: Hepatitis C virus (HCV) affects 1% - 2.5% of pregnancies. Universal screening is not recommended aside from those with risk factors including among others: intravenous or intranasal drug use, incarceration or those having a sexually transmitted infection. Our purpose was to assess the epidemiology of HCV in North Central Florida.

Methods: IRB approval was obtained for this retrospective descriptive study. Patients were identified through ICD-9 Diagnosis codes for HCV and pregnancy from 2009-2014. Data abstracted from medical records included demographic information, concomitant sexually transmitted infections, tobacco or substance abuse, transfusion history and tattoos.

Results: Of 17,081 patients, 275 patients were identified with HCV (prevalence 1.6%). Mean age of those infected was 27.3 years old (range 16 to 49) with 89.1% Caucasian and 7.3% African American. Concomitant infections with Hepatitis B, HIV, chlamydia and herpes simplex occurred in 9%, 0.7%, 16% and 12% of patients, respectively. Most HCV patients smoked tobacco (89%); one third smoked cannabis (34%). A history of intravenous drug use was present in 75% and cocaine use in 37.5%. Although not a classical risk factor for HCV, prescription narcotic use was reported among 2/3 patients whereas 44% took non-prescribed narcotics. A minority of women had exposure to either tattoos 28.5% or blood transfusion 15%.

Conclusion/Implications: We identified prescribed and self-administered oral narcotic medication and tobacco use as additional risks for HCV. We suspect adhering to the current screening recommendations permits cases of HCV to be missed and that more widespread if not universal screening should be considered.
    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.

Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.

Save Settings